Endocrine Abstracts

Introduction: Glycemic control and weight management are crucial considerations in the treatment of type 2 diabetes (T2D). Liraglutide, an incretin-based therapy, has been demonstrated to not only effectively maintain glycemic control but also promote weight loss in type 2 diabetic patients. Our study aims to evaluate the impact of Liraglutide on body weight and body composition parameters in patients with T2D.

Methods: This is a prospective study, carried out in the in the department of Endocrinology of the Military Hospital of Tunis. We administrated Liraglutide 1.2 mg daily at 22 patients with T2D. Weight and impedance measurements were performed on each patient before starting Liraglutide and after 6 to 12 months of treatment.

Results: Patients were 8 males and 14 females with a mean age of 53.8±8.9 years. Our patients had dyslipidemia, hypertension, heart failure and coronary artery disease in respectively 16, 14, one and seven patients. Twenty patients were obese, with morbid obesity in 16 patients. The mean weight was 109.7±17.9 kg before starting Liraglutide and 107.5±18.6 kg after 6 to 12 months of treatment (P=10⁻³). The mean BMI was 40±7.1 kg/m² before starting Liraglutide and 39.3±7.4 kg/m² after 6 to 12 months of treatment (P=0.834). The percentage of body fat decreased significantly after 6 to 12 months of treatment (44.1±7.7% vs 43.7±2.5%, P=0.046). There was no significant change in lean body mass (56.5±8.7% vs 56.6±8.7%, P=0.930).

Conclusion: Our study shows the effectiveness of Liraglutide in reducing weight and body fat percentage in patients with T2D.